We protect your health through science
Investigation
Respiratory viruses and Influenza
Research Lines
Content with Investigacion .
Virus Respiratorios y Gripe
• Gripe humana y animal. Vigilancia de su circulación. Antigripales, resistencias virales. Vacunas
• Infecciones víricas respiratorias en pacientes pediátricos • Diagnóstico, referencia y Nuevos procedimientos basados en la metagenómica viral para el estudio de virus respiratorios.
• Epidemiologia de Virus respiratorios: Gripe, Virus Respiratorio Sincitial, Adenovirus, Metapneumovirus humano, Coronavirus (MERS, 229E, OC43, HKU1, NL63), Parainfluenzavirus, Rinovirus, Bocavirus humano
• Virus respiratorios emergentes • Biodefensa y virus
Research projects
Projects with public funding
TITLE: Virulence factors of pathogenic yeasts and their influence on the host.
FUNDING ENTITY: Ministry of Education and Science.
POSITION HELD: Principal Investigator, Contracted “Ramón y Cajal”.
START/FINISH: 2006-2007
AMOUNT: 15,000 EUROS
TITLE: Characterization of fungal giant cells and their role during infection in mammals.
FINANCING ENTITY: Instituto de Salud Carlos III
POSITION HELD: Principal Investigator, Contracted “Ramón y Cajal”.
START/FINISH: 2006-2007
AMOUNT: 55,000 EUROS
TITLE: Search and identification of genes involved in the resistance to antifungal agents in
Cryptococcus neoformans
FUNDING ENTITY: Ministry of Science and Innovation.
POSITION HELD: Principal Investigator, Contracted “Ramón y Cajal”.
START/FINISH: 2008-2010
AMOUNT: 25,000 EUROS
COLLABORATORS: Juan Luis Rodríguez Tudela (National Center of Microbiology, ISCIII. Madrid); Manuel Cuenca Estrella (National Center of Microbiology, ISCIII. Madrid); Maria Jose Gianinni (Faculdade de Ciências Farmacêuticas-UNESP). Brazil
TITLE: Role of morphological changes of the pathogenic yeast Cryptococcus neoformans during host infection.
FUNDING ENTITY: Ministry of Science and Innovation. National Plan Program “Non-oriented Fundamental Research”, area of Biomedicine, SAF2008-03761.
POSITION HELD: Principal Investigator, Contracted “Ramón y Cajal”.
START/END: 2009-2011
AMOUNT: 46,000 EUROS
PROJECT TITLE: Identification of the molecular mechanisms involved in the morphogenesis of Cryptococcus neoformans and study of their function during infection.
FUNDING ENTITY: Ministry of Science and Innovation, National Plan for Non-Oriented Fundamental Research, Biomedicine Area, Referencia: SAF2011-25140
DURATION FROM: January 2012 UNTIL: December 2014
PRINCIPAL INVESTIGATOR: Oscar Zaragoza Hernández
This project has an FPI grantee granted.
SUBSIDY: 90.000 euros
TITLE: Importance of morphogenesis in the virulence of pathogenic yeast Cryptococcus neoformans and improvement of amphotericin B-based cryptococcosis therapy. Reference: SAF2014-25140
FUNDING ENTITY: MINECO (Call for R+D+I Projects “RETOS INVESTIGACION)
POSITION HELD: Principal Investigator
START/FINISH: 2015-2017
Funding: 100.000 €.
TITLE: Study of the molecular basis and factors inducing morphological changes in Cryptococcus neoformans and characterization of new therapeutic strategies. Reference: SAF2017-86912-R
FUNDING ENTITY: MINECO (Call for R+D+I Projects “RETOS INVESTIGACION)
POSITION HELD: Principal Investigator
START/END: 2018-2020
Funding: 106.000 €.
TITLE: Mechanisms of adaptation of the pathogenic yeast Cryptococcus neoformans to the lung. Reference: PID2020-114546RB
FUNDING ENTITY: Ministry of Science and Innovation, State Research Agency (Call “Proyectos I+D+I” 2020 - Modalities “Research Challenges” and “Knowledge Generation”).
POSITION HELD: Principal Researcher
START/END: 01/09/2021-31/05/2025
Funding: 117,000 €.
TITLE: Precision medicine against antimicrobial resistance. MePRAM Project.
FUNDING ENTITY: Research Projects on Precision Personalized Medicine of the Strategic Action in Health 2021-2023, under the PERTE for Vanguard Health and charged to the European funds of the Recovery, Transformation and Resilience Plan.
POSITION: Collaborator (Principal Investigator: Jesús Oteo Iglesias)
START/FINISH: 2023-2025
Funding: 4.339.500 €.
TITLE: Centre for Biomedical Research in Network. Infectious Diseases Area (CIBERINFEC)
Funding Agency: Insituto de Salud Carlos III. Reference: CB21/13/00105
Dates: 2022-2026 Funding: 85.000 € (first year)
PI: Emilia Mellado Terrado / CoPI: Óscar Zaragoza Hernández
TITLE: Study of the genetic, metabolic and cellular determinants that influence titan cell formation in the fungal pathogen Cryptococcus neoformans and correlation with antifungal exposure.
CALL FOR PROJECTS: Knowledge Generation Projects.
FUNDING ENTITY. State Research Agency. Ministry of Science, Innovation and Universities.
REFERENCE: Project PID2023-148686OB-I00 Project funded by MICIU/AEI/10.13039/501100011033 and by FEDER, EU.
PRINCIPAL INVESTIGATOR: Oscar Zaragoza Hernández
START/END: 2024-2027
FUNDING: 180.000 €.
TITLE: Characterization of azole-resistant Candida parapsilosis isolates associated with hospital outbreaks: New strategies for their detection and treatment.
CALL: Strategic Action in Intramural Health.
FUNDING ENTITY. Carlos III Health Institute.
REFERENCE: AESI-2024 PI24CIII/00051
PRINCIPAL RESEARCHER: Oscar Zaragoza Hernández / Laura Alcázar Fuoli
START/FINISH: /01/012025-31/12/2027
FUNDING: 70.000 €.
Projects financed by biotechnology companies
PROJECT TITLE: Amphores. Evaluation of the induction of oxidative damage by Amphoterin B in susceptible and resistant yeast species.
FUNDING ENTITY: Gilead
DURATION FROM: 2011 TO: 2012
PRINCIPAL INVESTIGATOR: Oscar Zaragoza Hernández
GRANT: 55,000 euros
TITLE: Fungomics. Evaluation of the activity of amphotericin B and other antifungals against human pathogenic fungi.
FINANCING ENTITY: Gilead
POSITION HELD: Principal Investigator
START/END: 2019-2020
TITLE: Antifungal susceptibility testing of a set of Candida spp to CD101 and anidulafungin in five microdilution plates.
FUNDING ENTITY: Cidara
POSITION HELD: Principal Investigator
START/END: 2018
TITLE: Cidara MultiCentre EUCAST study
FUNDING ENTITY: Cidara
POSITION HELD: Principal Investigator
START/END: 2016
TITLE: Characterization of triazole-resistant Candida parapsilosis isolates from Spanish hospitals
FUNDING ENTITY: Gilead Science
POSITION HELD: Principal Investigator
START/END: 2022-2023
TITLE: EUCAST multicentre MIC testing of manogepix meeting EUCAST ECOFF setting criteria
FUNDING ENTITY: Pfizer
POSITION HELD: Principal Investigator
START/END: 2023
Concesión del Proyecto de la Convocatoria 2019 de RETOS-COLABORACIÓN: Desarrollo de kits diagnósticos mediante PCR multiplex en tiempo real en formato líquido y gelificado para la detección de enfermedades víricas y sepsis. RTC2019-007023-1 / MPY 292/20. IPs: Inmaculada Casas y Giovanni Fedele. 2020-2023. 442.653 €. Investigadoras colaboradoras: Mª Paz Sánchez-Seco, Ana Vázquez, Anabel Negredo.
Título del Proyecto: VIRUS DE LA FIEBRE HEMORRÁGICA DE CRIMEA-CONGO EN ESPAÑA: PAPEL DE LAS AVES MIGRATORIAS Y GARRAPATAS EN LA DIVERSIDAD VIRAL Y SUS EFECTOS EN LAS PRESENTACIONES CLÍNICAS EN EL HOMBRE
Entidad financiadora: ISCIII. Expediente: PI21CIII/0001 Centro: CNM
Duración desde: 01/01/2022 hasta: 31/12/2024
Investigador principal: Mª Paz Sánchez-Seco Financiación: 171.190,84 €
Título del Proyecto: Development of New Technologies to Track Emerging Infectious Threats in Wildlife and the Environment (NEXTHREAT)
Entidad financiadora: Ministerio de Ciencia e Innovación. Convocatoria Proyectos de I+D+i en líneas estratégicas, en colaboración público-privada 2021. Expediente: Proyecto PLEC2021-007968 financiado por MCIN/AEI/10.13039/501100011033 y por la Unión Europea NextGenerationEU/ PRTR. Centro: ISCIII
Duración desde: 20/12/2021 hasta: 30/09/2025
Investigador principal: Ana Vázquez Financiación: 301.191 €
Título del Proyecto: Measuring the real impact of West Nile virus infection in Spain
Entidad financiadora: Convocatoria Intramural de Proyectos de Investigación 2022 pertenecientes a CIBERESP. Expediente: ESP22PI05/2022 Centro: ISCIII
Duración desde: 01/05/2022 hasta: 01/05/2024
Investigador principal: Ana Vázquez Financiación: 48.000 €
Título del Proyecto: Microsoft Premonition
Entidad financiadora: ISCIII. Expediente: MPY241-22 Centro: ISCIII
Duración desde: 01/07/2022 hasta: 30/06/2024
Investigador principal: Ana Vázquez Financiación: 160.000 €
Título del Proyecto: CIBER (Centro de Investigación Biomédica En Red) de Enfermedades Infecciosas (CIBERINFEC). CB21/13/00110.
Entidad financiadora: Instituto de Salud Carlos III. Centro: CNM, ISCIII
Duración desde: 01/01/2022 hasta:
Investigador principal: Mª Paz Sánchez-Seco Financiación: 60.000 €/año
Título del Proyecto: Acción Estratégica Monkeypox
Entidad financiadora: CIBER (Centro de Investigación Biomédica En Red) de Enfermedades Infecciosas (CIBERINFEC). Instituto de Salud Carlos III. Centro: Multicéntrico
Duración desde: 01/09/2022 hasta: 15/04/2023
Investigador principal: Mª Paz Sánchez-Seco Financiación: 214.000 €
Título del Proyecto: INVESTIGACION Y VIGILANCIA INTEGRADA DE LOS ARBOVIRUS EMERGENTES WEST NILE, TOSCANA Y DENGUE EN ALGUNAS ZONAS DE ESPAÑA
Entidad financiadora: ISCIII Expediente: PI19CIII/00014 Centro: ISCIII
Duración desde: 01/01/2020 hasta: 01/01/2022
Investigador principal: Ana Vázquez Financiación: 122.000 €
Título del Proyecto: RED TEMÁTICA DE INVESTIGACIÓN COOPERATIVA EN ENFERMEDADES TROPICALES
Entidad financiadora: ISCIII Expediente: RD16CIII/0003/0003. Centro: ISCIII
Duración desde: 2017 hasta: 2021
Investigador principal: Mª Paz Sánchez-Seco Financiación: 195.000 €
Título del Proyecto: INVESTIGACIÓN APLICADA AL DIAGNÓSTICO Y TRATAMIENTO DE LOS VIRUS ZIKA, DENGUE Y CHIKUNGUNYA
Entidad financiadora: ISCIII Expediente: PI16CIII/00037 Centro: ISCIII
Duración desde: 01/01/2017 hasta: 31/12/2020 (Incluida prórroga de un año)
Investigador principal: Mª Paz Sánchez-Seco Financiación: 145.000 €
Título del Proyecto: SHARP: Strengthened International HeAlth Regulations and Preparedness in the EU
Entidad financiadora: UE Centro: ISCIII
Duración desde: 01/10/2019 hasta: 01/10/2020
Investigador principal: Mª Paz Sánchez-Seco Financiación: 22.000 €
CURRENT PROJECTS
Project title: "Biochemical and functional characterisation of salivary proteins of Phlebotomus perniciosus and their role in infection by Leishmania infantum (PERNIPROT)"Reference: Project PID2023-147773NA-I00 funded by MICIU/AEI/10.13039/501100011033 and by FEDER, EU.
Start date: 01/09/2024
End date: 31/08/2028
Funding: €175,000
Principal investigator: Inés Elena Martín Martín.
Funding agency: Agencia Estatal de Investigación (Proyecto de Generación del Conocimiento 2023).
Project title: "Surveillance of leishmaniasis in the Community of Madrid from a “One Health” perspective: study of the infectious capacity of patients with visceral leishmaniasis and their role as reservoirs"
Reference: PI24CIII/00026
Start date: 01/01/2025
End date: 31/12/2027
Funding: €60,000.00
Principal investigator: Inés Elena Martín Martín.
Co-principal investigator: Maribel Jiménez Alonso
Funding agency: Instituto de Salud Carlos III (Strategic Action in Intramural Health, AESI).
Service Contract: "Analysis for the surveillance of the vector and wild reservoirs that transmit leishmaniasis in the Community of Madrid"
Reference: file no. 17/2024 (A/SER-008455/2024).
Start date: 26/06/2024
End date: 10/12/25, extendable to 2026
Total funding: €171,084
Principal Investigator: Maribel Jiménez Alonso
Funding agency: Service Contract between the Instituto de Salud Carlos III and the Directorate-General for Public Health, Regional Ministry of Health of the Community of Madrid
Project Title: CIBERINFEC Research Group (CB21/13/00110)
Start date: 2021
End date: currently active
Principal Investigator: Dr. Mª Paz Sánchez-Seco, Arbovirus and Imported Viral Diseases Unit.
Researchers from the Medical Entomology Laboratory: Maribel Jiménez (member), Inés Martín Martín (collaborator).
Funding: €108,134. File number: CB21/13/00110.
Funding agency: Consortium Centre for Biomedical Research in NETWORK (CIBER)
PAST PROJECTS
Service Contract: "Evaluation of the anti-leishmania effect of the bacteria Tc1 and its derivatives in the intravectorial cycle"
Reference: ISCIII-06896
Start date: 15/12/2022
End date: 15/04/2025
Funding: €71,265.67
Principal Investigator: Inés Elena Martín Martín
Funding agency: Service Contract between the company GlaxoSmithKline R&D (GSK) and the Instituto de Salud Carlos III
Service Contract: "Analysis for the surveillance of the vector and wild reservoirs that transmit leishmaniasis in the Community of Madrid"
Reference: 59/2020 (A/SER-040739/2020)
Start date: 10/12/2021
End date: 10/12/2023.
Funding: €42,612.17 per year Total 2021-2023: €127,836.51
Principal Investigators: Ricardo Molina /Maribel Jiménez Alonso
Funding agency: Service contract between the Instituto de Salud Carlos III (ISCIII) and the Directorate-General for Public Health, Regional Ministry of Health of the Community of Madrid
Project title: "Research and Integrated Surveillance of Emerging Arboviruses West Nile, Toscana and Dengue in some areas of Spain"
Reference: PI19CIII/00014
Start date: 2020
End date: 2022
Principal Investigator: Ana Vázquez González
Co-Principal Investigator: Ricardo Molina
Funding: €60,000.00
Funding agency: Instituto de Salud Carlos III (Strategic Action in Intramural Health, AESI).
Project title: "Characterisation of the concept of ‘asymptomatic carrier’ in leishmaniasis: implications for treatment".
Start date: 01/01/2015
End date: 31/12/2017
Principal investigators: Javier Moreno and Javier García
Funding: €159,940
Funding agency: Study Agreement between Drugs for Neglected Diseases Initiative (DNDi), the Spanish Foundation for International Cooperation, Health and Social Policy (FCSAI) and Fuenlabrada Hospital. Subcontractor: ISCIII Medical Entomology Unit (Maribel Jiménez and Ricardo Molina).
Project title: "Biology and control of vector-borne infections in Europe (EDENext Collaborative Project): Sandfly-borne diseases".
Reference: Subproject (PBD) (EU, FP7-HEALTH-2010-single-stage, contract No. 261504).
Start date: 2011
End date: 2014
Principal investigator: Ricardo Molina General coordinator: Petr Volf
Funding: €140,000
Funding agency: EU-FP7
Project Title: "Phlebotomus perniciosus saliva as a source in the search for potential targets for the development of vaccines against Leishmania infantum"
Reference: AGL2008-01592/GAN (MICINN)
Start date: 2009
End date: 2011
Principal investigator: Ricardo Molina
Funding: €70,180
Funding agency: Ministry of Science and Innovation
Los proyectos del grupo de los últimos años son los siguientes:
Proyecto “Enfoques inmunoinformaticos e inmunoproteomicos para identificar epitopos bacterianos implicados en la REA: diagnostico temprano y diseño de farmacos” financiado por el Plan Nacional de I+D+i del Ministerio de Ciencia, Innovación y Universidades. Centro Nacional de Microbiología, Instituto de Salud Carlos III. Investigador principal. Año: 2024-2026. Presupuesto Concedido: 225.000 euros. Proyecto PID2023-148729OB-100 financiado por MICIU/AEI/10.13039/501100011033 y por FEDER, UE.
Proyecto “La interrelación de CD69 y el procesamiento antigénico en enfermedades infecciosas y autoinmunes" financiado por la Acción Estratégica en Salud del Ministerio de Ciencia, Innovación y Universidades. Año: 2023-2025.
Proyecto “Interacciones génicas y proteicas de CD69 y sus regiones génicas reguladoras con moléculas" inanciado por el Plan Nacional de I+D+i del Ministerio de Ciencia, Innovación y Universidades. Centro Nacional de Microbiología, Instituto de Salud Carlos III. Proyecto PID2021-125757OB-100 financiado por MICIU/AEI/10.13039/501100011033 y por FEDER, UE.
Proyecto “Nuevas tecnologías de fabricación y optimización de tejidos: la piel como sistema modelo” financiado por el Programa de Actividades de I+D entre grupos de investigación de la Comunidad de Madrid en tecnologías 2018. Año: 2020-2023. Proyecto Coordinado por el Dr. Pablo Acedo de la Universidad Carlos III.
Proyecto “Estudio de CD69 como diana para mejorar el tratamiento de la leucopania y la movilización de células T de memoria de médula ósea" financiado por la Acción Estratégica en Salud del Ministerio de Ciencia, Innovación y Universidades. Año:2020-2024.
Proyecto “Diseño racional de una vacuna contra el virus respiratorio sincitial humano” financiado por la Acción Estratégica en Salud del Ministerio de Ciencia, Innovación y Universidades. Año: 2019-2022
Proyecto “Función de CD69 y sus elementos reguladores" financiado por la Acción Estratégica en Salud del Ministerio de Ciencia, Innovación y Universidades. Año: 2017-2022.
Proyecto “Diseño de vacunas recombinantes poliepitópicas para generar respuestas CD8+ contra virus emergentes” financiado por el Plan Nacional de I+D+i del Ministerio de Economía y Competitividad. Año: 2015-2017.
Proyecto “Análisis de los efectos de CD69 dependientes de S1P1 en modelos de infección e inflamación y estudio de su regulación” financiado por el FIS. Año: 2014-2017.
Proyecto “ADELVAC: Adenovirus con delecciones epitópicas para vacunación” financiado por el programa INNPACTO del Ministerio de Economía y Competitividad. Centro Nacional de Microbiología, Instituto de Salud Carlos III. Año: 2012-2014. Proyecto Coordinado por el Dr. Manel Cascallo de VCN BIOSCIENCES SL.
Proyecto “Diseño de vacunas multiepitópicas recombinantes para aumentar la respuesta inmune celular contra el VRSH” financiado por el Plan Nacional de I+D+i del Ministerio de Ciencia e Innovación. Año: 2012-2014.
A) Proyectos de investigación financiados en los últimos 10 años
-
Como investigadora principal
1. Impact of long-tem HCV eradication on HIV infection: integration of Immune-virologic HIV markers, host transcriptome, and plasma microbiome data. Ministerio de Ciencia (Proyectos de Generación de Conocimiento 2021). Expediente: PID2021-126781OB-I00 financiado por por MICIU/AEI /10.13039/501100011033 y por FEDER, UE Septiembre 2022 - agosto 2025. 157.300€.
2. Identificación de biomarcadores inmunológicos asociados a las infecciones virales crónicas hepatitis C y VIH relacionados con la infección por SARS-COV-2 y su pronóstico. Consejo de Educación e Investigación. Comunidad de Madrid. Doctorados Industriales. Expediente: IND2020/BMD-17373. 2021-2024. 150.000€.
3. Impacto de la erradicación y aclaramiento del VHC con los nuevos antivirales de acción directa, en pacientes coinfectados VIH/VHC en el reservorio VIH en sangre periférica y sistema inmune. Organismo Financiador: Fondo de Investigación Sanitaria (ISCIII). Expediente: PI18CIII/00020. 2019-2021. 154.000€.
4. Desarrollo de un sistema de diagnóstico in vitro para la determinación del virus de la Hepatitis C mediante nanosondas. Organismo Financiador: Comunidad Autónoma de Madrid. Doctorados Industriales. Expediente: IND2017/BMD7683. 2018-2020. 128.000€.
5. Validación preclínica de un nuevo método de diagnóstico in vitro para la determinación de la infección por el virus de la hepatitis C en humanos. Organismo financiador: BioAssays SL. Expediente: MVP-325/19. 2019-2023. 193.400€.
6. Estudio del reservorio VIH en sangre periférica y su relación con la infección por VHC, sistema inmune y perfil de microARNs. Organismo Financiador: Fondo de Investigación Sanitaria (ISCIII). Expediente: PI15CIII/00031. 2016-2018. 154.000€.
7. Development of a cell-based assay to characterize resistance mutations and drug susceptibility to protease inhibitors against hepatitis C virus and evaluation in vivo as predictors of failure. Organismo Financiador: Fondo de Investigación Sanitaria (ISCIII). Expediente: CP13/00098. 2014-2016. 120.000€.
- Como investigadora asociada
1. URBANOME (Urban Observatory for Multi-participatory Enhancement of Health and Wellbeing). IP: Saúl García Dos Santos-Alves. Agencia Financiadora: Horizon 2020 H2020-SC1-BHC-2018-2020 / H2020-SC1-2020-Two-Stage-RTDework. Call topic: Innovative actions for improving urban health and wellbeing - addressing environment, climate and socioeconomic factors". Expediente: 945391. 01/04/2021 - 01/04/2025. 268.000 €.
2. Antibiotics, hormones, persistent and mobile organic contaminants and pathogens, the complex mixture in agriculture and livestock scenario. Risk to health or natural attenuation? (Nat4Health). IP: Ana de Santiago y Raffaella Meffe. Agencia Financiadora: Ministerio de ciencia e Innovación. Convocatoria: Proyectos I+D+i 2020. Modalidad: Retos Investigación. Expediente: PID2020-118521RB-I00. 01/09/2021 - 01/09/2025. 170.000 €.
3. Inmunopatogenía del VIH. Red Temática De Investigación Cooperativa (RIS). Expediente: RD16CIII/00025. IP: Salvador Resino. (Instituto de Salud Carlos III). 01/01/2017-06/03/2022. 250.000 €.
4. Efectos de la erradicación del VHC en pacientes con cirrosis avanzada por VHC. Una aproximación traslacional. Investigador principal: Salvador Resino García. Organismo Financiador: Fondo de Investigación Sanitaria (ISCIII). Expediente: PI14/CIII/00011. 2016-2018. 154.000 €.
5. Desarrollo y mecanismo de acción de dendrímeros como microbicidas para frenar la infección por el VIH por transmisión sexual (vaginal y anal): prueba de concepto. IP: Mª Angeles Muñoz Fernández. Organismo Financiador: Fondo de Investigación Sanitaria (ISCIII). Expediente: PI13/02016. 2014-2016. 180.000 €.
6. Peptides-associated dendrimers in dendritic cells for the development of new nano-HIV vaccines. DENPEPTHIV. EuroNanoMed. IP: Mª Angeles Muñoz Fernández. Organismo financiador: Instituto de Salud Carlos III. Proyectos al amparo del Espacio Europeo de Investigación dentro del VII Programa Europeo. FP7 Cooperation Work Programme: Health-2010. Expediente: PS09102669. 2010-2013. 220.000 €.
1: Título del proyecto: Desarrollo de enzibióticos para combatir infecciones en pacientes con fibrosis quística provocadas por los patógenos Pseudomonas aeruginosa y Staphylococcus aureus: CF-TREAT
Referencia: CPP2022-009574 / MPY 375/23
Agencia Financiadora: Agencia Estatal de Investigación. MICINN.
Fecha Inicio: 01/12/2023
Fecha Fin: 30/11/2026
Financiación: 238.938 Euros
Investigadores principales: Roberto Díez Martínez, José E. Yuste Lobo y Pilar García Suárez
2: Título del proyecto: Desarrollo de enzibióticos para combatir infecciones humanas producidas por Enterococcus faecium resistente a vancomicina (ANTI‐VRE).
Proyecto CPP2021-009054 financiado por MICIU/AEI /10.13039/501100011033 y por la Unión Europea NextGenerationEU/ PRTR
Investigadores principales: Roberto Díez Martínez, Jose Yuste Lobo y Mirian Domenech
Periodo: 18/11/2022 - 17/11/2025
Cuantía total: 231.455 €
3: Título del proyecto: Mecanismos de virulencia en patógenos respiratorios.
Entidad financiadora: Ministerio de Ciencia e Innovación, Agencia Estatal de Investigación (Convocatoria «Proyectos I+D+I» 2020 - Modalidades «Retos Investigación» y «Generación de Conocimiento»). Referencia: PID2020-119298RB-I00
Investigador principal: Jose Yuste Lobo
Periodo: 01/09/2021 - 30/08/2024
Cuantía total: 121.000 €
4: Título del proyecto: Efectividad de la vacuna antineumocócica conjugada 13-valente frente a la hospitalización por neumonía adquirida en la comunidad en adultos de 60 años o mayores, mediante un estudio de casos y controles modificado. Estudio CIBELES.
Investigadores principales: Jose Yuste Lobo y Ángel Gil de Miguel
Entidad financiadora: PFIZER. Referencia: MVP 249/20
Periodo: 23/02/2021 - 22/02/2025
Cuantía total: 168.000 €
5: Título del proyecto: Evolution of Invasive Pneumococcal Disease in Spain with special focus on the pathogenesis of serotypes 3, 8, 11A, 19A, 22F and 33F. Investigadores principales: Jose Yuste Lobo y Mirian Domenech.
Entidad financiadora: Merck Sharp & Dohme USA. Referencia: MVP 132/21
Período: 16/06/2021 - 15/12/2023
Cuantía total: 157.448€
6: Título del proyecto: Mecanismos de patogenicidad y protección en bacterias Gram-positivas causantes de enfermedad respiratoria y bacteriemia
Investigador principal: Jose Yuste Lobo
Entidad financiadora: MINECO. Referencia: SAF2017-83388-R
Periodo: 31/12/2017 - 30/06/2021
Cuantía total: 145.200 €
7: Título del proyecto: Characterization of susceptibility to cefditoren investigating penicillin resistant clinical isolates of Streptococcus pneumoniae.
Investigadores: Jose Yuste Lobo y Mirian Domenech Lucas
Entidad financiadora: Tedec Meiji Farma, S.A. Referencia: MVP 119/20
Periodo: 11/07/2020 – 10-07-2022
Cuantía total: 76.517 €
8: Título del proyecto: Impact of clinical isolates of serotypes 22F and 33F in the epidemiology and pathogenesis of Streptococcus pneumoniae.
Investigador principal: Jose Yuste Lobo
Entidad financiadora: Merck Sharp & Dohme España, S.A. Referencia: MVE 213/18
Periodo: 10/05/2018 - 30/05/2021
Cuantía total: 157.604 €
1. Immune response to SARS-CoV-2 infection: effect in naïve vaccinees and seropositives against the most transmissible variants and relevance of host genetics.
Principal Investigator: Javier García Pérez.
Funding Agency: Acción Estratégica en Salud Intramural 2021(ISCIII)
Funding: 135.000 €
Duration: 2022-2025.
Project Reference: PI21CIII/00025.
2. Design and generation of viral stocks of new SARS-CoV-2 variants (omicron subvariants) and analysis of their susceptibility to antibodies neutralization.
Principal Investigator: Javier García Pérez.
Funding Agency: Hipra Scientific S.L.U.
Funding: 103.771 €
Duration: 2023-2025.
Project Reference: MVP 198/23.
3. Characterization of a mutation in transportin 3 that protects against HIV infection: molecular mechanisms and discovery of new drugs.
Principal Investigator: José Alcamí y Javier García Pérez.
Funding Agency: Proyectos de I+D+I, Generación de Conocimiento y Retos Investigación de la Agencia Estatal de Investigación.
Funding: 240.000 €
Duration: 2022-2026.
Project Reference: PID2021-125978OB-C21 funded by MICIU/AEI/10.13039/501100011033 and by FEDER, UE
4. Generation of immunogens based on HIV-1 envelopes from acutely infected individuals with a broad neutralizing response against founder viruses.
Principal investigator: Nuria González Fernández.
Funding Agency: Acción Estratégica en Salud Intramural 2023 (ISCIII)
Funding: 82.000 €
Duration: 2024-2026.
Project Reference: PI23CIII/00039.
5. Phase 1 clinical trial to evaluate the safety and immunogenicity of HIV-1 envelope-based 763SIP8/MPLA-5 vaccine.
Principal Investigator: Josep Mallolas Masferrer.
Funding Agency: Proyectos de Investigación Clínica Independiente, Acción Estratégica en Salud 2021-2023 (ISCIII).
Funding: 173.200 €
Duration: 2024-2026.
Project Reference: ICI23/00025.
6. Service of immunological determinations of the ENE-COVID SENIOR II protocol.
Principal Investigator: Mayte Pérez Olmeda y Javier García Pérez.
Funding Agency: Fundación para la investigación biomédica del Hospital Universitario La Paz
Funding: 185.037 €
Duration: 2024-2025.
Project Reference: MOTR 219/24.
7. Characterization of the immune memory against SARS-CoV-2 in a population over 65 years of age using single cell transcriptomics.
Principal Investigator: Javier García Pérez y Francisco Díez Fuertes.
Funding Agency: Acción Estratégica en Salud Intramural 2021(ISCIII)
Funding: 152.000 €
Duration: 2025-2027.
Project Reference: PI24CIII/00058
8. Evaluation of rimonabant and cannbinooid analogues in HIV infection and viral latency.
Principal Investigator: Luis Miguel Bedoya del Olmo.
Funding Agency: Universidad Complutense de Madrid
Funding: 12.000 €
Duration: 2024-2025.
Project Reference: PR12/24-31553.
9. Discovery of new inhibitors of HIV-1 RNA biogenesis based on blocking the ribonucleoprotein RRE-Rev.
Principal Investigator: José Gallego Sala. Associate Researcher: Luis Miguel Bedoya del Olmo
Funding Agency: Department of Innovation, Universities, Science and Digital Society. Generalitat Valenciana.
Funding: 543,683.84 €
Duration: 2025-2027.
Project Reference: PROMETEO/2021/036.
PROJECT TITLE: Consorcio Centro de Investigacion Biomedica en Red (CIBER). Infectious Diseases Area.
Funding Agency: CIF: G85296226. Reference: CB21/13/00105
Dates: 2022-2026 Funding: 85.000 € (first year)
Principal Investigator: Emilia Mellado Terrado
PROJECT TITLE: Modulación diferencial de la persulfidación en el hongo y el hospedador como nueva estrategia antifúngica.
Funding Agency: Agencia Estatal de Investigación (Convocatoria Proyectos de Generación de Conocimiento"
Reference: Project PID2022-136343OA-I00 funded by MICIU/AEI /10.13039/501100011033 and by FEDER, UE
Principal Investigator: Jorge Amich.
Dates: 2024-2026.
Funding: 118.750 €
PROJECT TITLE: : Bridging the gap between environment and patient JPIAMR (AC23CIII_2/00002 (JPIAMR2023-DISTOMOS-103).
DATES: 2024-2026 Funding: 178.000 €
Principal Investigator: Jorge Amich.
PROJECT TITLE: : Buscando los rasgos geneticos de la resistencia de Aspergillus fumigatus a los azoles para preservar la eficacia de los azoles:un enfoque de salud global.
FUNDING AGENCY: Fondo de Investigación Sanitaria. PI21CIII/00028_ MPY443/2021
DATES: 2022-2025 Funding: 47.000 €
Principal Investigator: Emilia Mellado Terrado
PROJECT TITLE: : Persistencia a antifúngicos azólicos en Aspergillus fumigatus: mecanismos, relevancia y diagnóstico.
FUNDING AGENCY: AESI 2022 (PI22CIII/00053).
DATES: 2023-2025 Funding: 55.000 €
Principal Investigator: Jorge Amich.
PROJECT TITLE: : La medicina de precisión contra la resistencia a antimicrobianos:
CONSORCIO CENTRO DE INVESTIGACION BIOMEDICA EN RED (CIBER) CENTRO NACIONAL DE MICROBIOLOGIA
G85296226 PMP22/00092. Project MePRAM 28.107.46QF.749 Funding: 4.339.500,00€
Principal Investigator: Jesus Oteo
Research Projects as Principal Investigators
Effect of Feminizing Hormone Therapy on the Immune Response in Transgender Women
Principal Investigator: Víctor Sánchez-Merino
Funding Agency: Intramural Health Strategic Action
Funding: €117,000
Participating Institutions: ISCIII, IRSICAIXA, 7 Infectious diseases units (Hospital General Universitario Gregorio Marañón (HGUGM-INF), Hospital Universitario La Paz (HULP), Hospital Universitario Infanta Leonor (HUIL), Hospital Fundación Jiménez Díaz (FJD), Fundación Universitario la Princesa (HUP), Hospital Universitario Ramón y Cajal (HURyC) y Hospital Universitario Doce de Octubre (HU12O), Centro Sandoval, 1 Gender Identity Unit, Facultad de psicología (UAM), Facultad de Geografía e Historia (UCM) and three ONGs
Duration: 01/01/2025- 31/12/2027
Project Reference: PI24CIII/00031
Design of Vaccine Prototypes based on HIV-1 Envelope presented on Virus-Like Particles and Nanodiscs
Principal Investigator: Eloísa Yuste Herranz
Funding agency: Knowledge Generation Projects. State Plan for Scientific and Technical Research and Innovation.
Funding: €125,000
Participating Institutions: ISCIII and University of UNSW (Sydney, Australia)
Duration: 01/09/24–31/12/28
Reference: Project PID2023-148729OB-100 funded by MICIU/AEI/10.13039/501100011033 and by FEDER, UE.
Funding for Research Assistant Position. Project: New Approaches to Immunogen Design for the Induction of Anti-HIV-1 Broadly Neutralizing Antibodies (bNAbs) Based on Viral Envelope Proteins Presented on VLPs
Principal Investigator: Eloísa Yuste Herranz
Funding Agency: Youth Employment Plan (Community of Madrid)
Funding: Hiring of a senior graduate for 2 years
Participating Institutions: ISCIII
Duration: 01/04/2024 – 31/03/2026
Project Reference: SAL-GL-28125
Generation of an Adenovirus-Associated Vector for the Delivery of a Broadly Neutralizing Antibody (bNAb) Against HIV-1 That Does Not Induce Anti-Antibody Responses. Funding for Research Assistant Position.
Principal Investigator: Víctor Sánchez Merino
Funding Agency: FUAX-Santander
Funding: €90,000
Participating Institutions: Universidad Alfonso X El Sabio and ISCIII
Duration: 01/04/2022 – 01/04/2025
Project Reference: 1.013.008
New Approaches to Immunogen Design for the Induction of Anti-HIV-1 Broadly Neutralizing Antibodies (bNAbs) Based on Viral Envelope Proteins Presented on Virus-Like Particles (VLPs).
Principal Investigator: Eloísa Yuste Herranz
Funding Agency: Intramural Health Strategic Action
Funding: €77,000
Participating Institutions: Fraunhofer Institute (Germany) and ISCIII
Duration: 01/01/2021 – 30/06/2024
Project Reference: PI20CIII/00039
Development of Immunogens and Vaccination Strategies to Optimize the Induction of Broadly Neutralizing Antibodies (bNAbs) Against HIV-1.
Principal Investigator: Eloísa Yuste Herranz
Funding Agency: Intramural Health Strategic Action
Funding: €117,000
Participating Institutions: Fraunhofer Institute (Germany) and ISCIII
Duration: 01/01/2018 – 31/12/2021
Personnel Hiring: One postdoctoral researcher for 3 years
Project Reference: PI17/00049
Isolation and Characterization of Broadly Neutralizing Antibodies Against HIV-1 from Recently Infected Patients.
Principal Investigator: Eloísa Yuste Herranz
Funding Agency: Health Strategic Action (ISCIII)
Funding: €57,475
Participating Institutions: IDIBAPS, Fraunhofer Institute (Germany), and ISCIII
Duration: 01/01/2014 – 30/04/2017
Project Reference: PI13/01528
Development of an HIV Vaccine: Isolation and Characterization of New Broadly Neutralizing Antibodies.
Principal Investigator: Eloísa Yuste Herranz
Funding Agency: Health Research Fund (ISCIII)
Funding: €116,765
Participating Institutions: IDIBAPS and ISCIII
Duration: 01/01/2010 – 31/12/2012
Project Reference: PI09/1459
Optimization of the HIV-1 Envelope Protein as an Immunogen.
Principal Investigator: Eloísa Yuste Herranz
Funding Agency: Spanish Foundation for AIDS Research and Prevention (FIPSE)
Funding: €141,845
Participating Institutions: IDIBAPS
Duration: 30/10/2008 – 31/08/2012
Personnel Hiring: One senior graduate for 3 years
Project Reference: 36780/08
Optimization of the HIV-1 Envelope Protein as an Immunogen.
Principal Investigator: Eloísa Yuste Herranz
Funding Agency: Ramón y Cajal Program (Ministry of Education and Science)
Funding: 5-year Ramón y Cajal Researcher contract + 3 years as I3
Participating Institutions: IDIBAPS
Duration: 2008 – 2016
Project Reference: RYC-2007-00788
R&D projects as part of the research team
Determination of factors associated with protection against Human Immunodeficiency Virus type 1 Reinfection: Identification of protection correlates.
Principal Investigator: María Pernas Escario
Funding Agency: Gilead Sciences
Funding: €16,630
Participating Entities: Centro Sandoval and ISCIII
Duration: 01/01/2023 - 31/12/2023
Contract/Project File: GLD22/001144
EAVI2020: European AIDS Vaccine Initiative 2020
Principal Investigator: José Alcamí Pertejo
Funding Agency: Horizon 2020 (European Union; EU)
Funding: €403,829
Participating Entities: ISCIII and an EU consortium
Duration: 01/01/2015 - 30/04/2021
Contract/Project File: MPY1398/15
EHVA, European HIV Vaccine Alliance (EHVA): an EU platform for the discovery and evaluation of novel prophylactic and therapeutic vaccine candidates.
Principal Investigator: Felipe García Alcaide
Funding Agency: Horizon 2020 (European Union; EU)
Funding: €1,000,000
Participating Entities: IDIBAPS and an EU consortium
Duration: 01/01/2018 - 31/12/2020
Contract/Project File: 681032
Grup de Recerca VIH/SIDA
Principal Investigator: José María Gatell
Funding Agency: AGAUR_SGR14 (Generalitat de Catalunya-projects)
Funding: €63,000
Participating Entities: IDIBAPS
Duration: 01/01/2014 - 30/04/2017
Contract/Project File: 214_SGR_706
SIDA Vaccine Research Project (HIVACAT)
Principal Investigator: José María Gatell
Funding Agency: MINECO (INNPACTO Program)
Funding: €288,740
Participating Entities: IDIBAPS and Irsicaixa
Duration: 01/01/2013 - 31/03/2020
Contract/Project File: PT-2012-0325-010000
Design, synthesis, and anti-HIV-1 study of peptide domains of GB virus B
Principal Investigator: Isabel Haro
Funding Agency: Foundation for AIDS Research and Prevention (FIPSE)
Funding: €33,000
Participating Entities: IQAC-CSIC and IDIBAPS
Duration: 09/03/2010 - 30/11/2014
Contract/Project File: 36-0735-09
CURRENT PROJECTS: Award of the RETOS-COLABORATION 2019 Call for Proposals: Development of diagnostic kits using real-time multiplex PCR in liquid and gel format for the detection of viral diseases and sepsis.
Reference: RTC2019-007023-1 / MPY 292/20. Project funded by the Ministry of Science and Innovation and the State Research Agency.
PI: Inmaculada Casas and Giovanni Fedele.
Execution dates: 2020-2023.
Amount financed: 442,653 €.
Collaborator: Francisco Pozo
Título: Impact of vaccination against Human Papillomavirus in Spain: Studye of the distribution of genotypes and its application in surveillance. Principal Investigator: Horacio Gil. Starting/End dates: 2024-2026. Funding Entity: Acción Estratégica de Salud Intramural (AESI) del Instituto de Salud Carlos III. Project Reference: PI23CIII/00006.
Título: Effect of feminizing therapy on immune response in transgender women. Principal Investigator: Victor Manuel Sánchez Merino. Collaborating Investigator: Horacio Gil. Starting/End dates:2025-2027. Funding Entity: Acción Estratégica de Salud Intramural (AESI) del Instituto de Salud Carlos III. Project Reference: PI24CIII/00031.
Expresion
-Project “Induction, differentiation and modulation of resident B lymphocytes in the lung in response to pneumococcus (NEUBLUNG)”. Ministry of Science and Innovation, PID2022-141754OB-I00 Call 2022 "Knowledge Generation Projects". 09/01/2023-08/31/2026. Financed by MICIU/AEI /10.13039/501100011033 and by ERDF, EU. PI: Belén by Andrés Muguruza. CoPI: María Luisa Gaspar Alonso-Vega.
-Project." Immune response of the nasal mucosa in childhood bronchiolitis” Instituto de Salud Carlos III-AESI. AESI-PI22CIII/00030 PI: Belén by Andrés Muguruza. CoPI Maria Luisa Gaspar Alonso-Vega. 01/01/2023-12/31/2025..
-Project. BenBedPhar. CA20121, European Union. Antonio Cuadrado. (CNM-ISCIII).10/19/2021-10/18/2025.
-Spanish Association Against Cancer Project “Novel comprehensive immunotherapy to specifically target the malignant clone in Sézary syndrome, an ultra-rare cancer of mature T lymphocytes”, number PROYE20084REGU. PI: José Ramón Regueiro, PI group Maria Luisa Gaspar. 01/01/2021-12/31/2023.
Project “The pulmonary immune system in homeostasis and infection: characterization and function of immature and pseudoinnate lymphoid populations.” MINECO-RETOS RTI2018-099114-B-100. PI: Maria Luisa Gaspar, CoPI: Belén de Andrés 01/01/2019-12/31/2022. Financed by MICIU/AEI /10.13039/501100011033/ and by FEDER A way of making Europe.
-Project “New B lymphoid populations: B1-rel pseudoinnate cells, homeostatic maintenance and their response under infection conditions.” MINECO-RETOS SAF2015-70880-R. PI: Maria Luisa Gaspar. 01/01/2016-12/31/2019.
-Project “Role of CD19+CD45R lymphocytes- in perinatal immune responses. Implications related to respiratory diseases in neonates. AESI PI14CIII/00049; PI Belén de Andrés. 2015-2018.
-Project “Study of the pseudo-innate population of CD19+CD45R- B lymphocytes in TLR-dependent infection models”. AESI PI11/01733FIS. PI Belén de Andrés. 2012-2015.
-Project." Cellular interactions in the establishment of B lymphoid differentiation niches: role of megakaryocytes and their implications in pathology. MINECO; SAF2012-33916. Maria Luisa Gaspar. 01/01/2013-12/31/2015.
-ISCIII Platforms Project to support R&D&I in Biomedicine and Health Sciences. PT23CIII/00006. 2023. Participating researcher: Isabel Cortegano.
-Research contracts between the Carlos III Health Institute and Inmunotek S.L. for the development of the Bactek-mv130 and Uromune-MV140 study in protection against S. pneumoniae infections. Immunotek. IP: Belen de Andrés 2019-2021.
-Research contract between the Carlos III Health Institute and Inmunotek S.L. “MV130 as a vaccine model based on trained immunity against respiratory infections due to pneumococcus and respiratory syncytial virus”, CAM Call. Industrial Doctorates. IND2023/BMD-27071. PI: Belén by Andrés Muguruza. 12/01/2023-11/30/2026.
1) Project Title: Interaction Between DNA Supercoiling and Transcription in the Human Pathogen Streptococcus pneumoniae.
Principal Investigator: Adela González de la Campa
Funding Entity: Ministry of Science and Innovation, State Research Agency (Call for "R&D&I Projects" 2020 – "Research Challenges" and "Knowledge Generation" Modalities).
Reference: PID2021-124738OB-100.
Duration: 2022-2025.
Funding Amount: €108,900.
2) Project Title: Study of the Factors Organizing the Chromosome of Streptococcus pneumoniae: New Antibiotic Targets and Resistance Mechanisms.
Principal Investigator: Adela González de la Campa
Funding Entity: Ministry of Economy, Industry, and Competitiveness. State Research Agency.
Reference: BIO2017-82951-R.
Duration: 2018-2020.
Funding Amount: €169,400.
3) Project Title: Role of DNA Topoisomerases and Nucleoid-Associated Proteins in the Chromosome Organization of Streptococcus pneumoniae: Response to Antibiotics and Virulence.
Principal Investigator: Adela González de la Campa
Funding Entity: Ministry of Economy and Competitiveness. Secretariat of State for Research, Development, and Innovation.
Reference: BIO2014-55462.
Duration: 2015-2017.
Funding Amount: €193,600.
4) Project Title: The Control of Supercoiling Level in Streptococcus pneumoniae as an Antimicrobial Target.
Principal Investigator: Adela González de la Campa
Funding Entity: Ministry of Economy and Competitiveness. Secretariat of State for Research, Development, and Innovation.
Reference: BIO2011-25343.
Duration: 2012-2015.
Funding Amount: €209,000.
5) Project Title: Role of Small Non-Coding RNAs in the Pathogenicity of Streptococcus pneumoniae.
Principal Investigator: Mónica Amblar Esteban
Funding Entity: Ministry of Economy and Competitiveness. Strategic Health Action (AES).
Reference: PI11/00656.
Duration: 2012-2015.
Funding Amount: €198,714.
Proyectos en los que el Laboratorio ha participado como IP en los últimos años
- "La Coordinación de actividades de investigación en el CNM para realizar una respuesta integradora frente a la pandemia por SARS-CoV2 en España"
- “Estudio ENE_COVID_SENIOR: Prospective study to establish the immune status in the elderly after receiving a full course of vaccination”
- “Respuesta inmune frente a la infección por SARS-CoV-2: efecto en vacunados naive y en seropositivos frente a las variantes más transmisibles y relevancia de la genética del hospedador”.
- “Estudio de Seroprevalencia de Crimea-Congo”
Proyectos como colaboradores científicos
- “Multi-center, Adaptive, Randomized Clinical Trial of Convalescent Plasma Therapy Versus Standard of Care for the Treatment of COVID-19 in Hospitalized Patients”
- “Investigación y vigilancia integrada de los arbovirus emergentes West nile, toscana y dengue en algunas zonas de España”
- “Análisis epidemiológico y virológico de los agentes virales incluidos en la vacuna triple vírica: nuevos retos”
- “Estudio de Seroprevalencia de Crimea-Congo en poblaciones de riesgo”
- “Estudio ENE_COVID_SENIOR II: Prospective study to establish the immune status in the elderly after receiving a full course of vaccination”
Estudios relevantes
- “2º estudio de seroprevalencia en España”
- “Estudio Nacional de sero-epidemiología de la infección por SARS-Cov-2 en España, Estudio ENE-COVID”
- “A Phase 2, Comparative, Randomised, Adaptive Trial to Evaluate the immunogenicity against SARS-Cov2 and safety of boosted vaccination with COMIRNATY in subjects having received prime vaccination with VAXZERIA”. Estudio CombiVacs.
- “Estudio de respuesta de inmunogenicidad de las vacunas autorizadas contra la COVID-19 en sujetos que han recibido previamente una vacuna experimental”
- “Prospective study to establish the immune status in the elderly after receiving a full course of vaccination. ENE-COVID SENIOR I y II”
- “Estudio de Seroprevalencia de Crimea-Congo en grupos de riesgo”
Convenios y contratos de los últimos años
-“Estudio de sensibilidad y la especificidad clínica del ensayo Access SARS-CoV-2 IgG en el instrumento access2 de Beckman Coulter”
“Evaluación de ensayos de serología mediante la técnica de quimioluminiscencia flash con el analizador liaison XL”
“ENE-COVID SENIOR II Prospective study to establish the immune status in the elderly after receiving a full course of vaccination.”
1. Nombre del proyecto: Mejora del pronóstico del paciente con riesgo de enfermedad fúngica invasora: estudio de susceptibilidad del huésped y desarrollo de nuevos métodos de diagnóstico clínico. Entidad/es financiadora/s: Instituto de Salud Carlos III. Fecha de inicio-fin: 01/01/2018 - 31/12/2020. Cuantía: 72.000 €. Investigadores principales (IP, Co-IP,...): María José Buitrago Serna/Laura Alcazar Fuoli
2. Nombre del proyecto: Red española de Investigación en Patologías infecciosas REIPI
Entidad/es financiadora/s: ISCIII-FEDER Fecha de inicio-fin: 01/01/2017 - 31/12/2021
Cuantía total: 195.612 €. Coordinador: Emilia Mellado
3. Nombre del proyecto: Desarrollo y validación de un método de detección de tipo “point of care”. Entidad/es financiadora/s: Instituto de Salud Carlos III. Fecha de inicio-fin: 01/01/2015 - 31/12/2017. Cuantía total: 46.000 €. Investigador principal: María José Buitrago.
4. Nombre del proyecto: European Research Infrastructure on Highly Pathogenic Agents 2-ERINHA2(Horizon2020). Nombre del programa: FP7-Infraestructuras-2015. Programa marco. THEME (INFRA-2010-2.2.8: High Security BLS4 Laboratory). Entidad financiadora: Unión Europea. Fecha de inicio-fin: 01/01/2016 - 01/06/2017. Cuantía total: 524.848 €. Cuantía subproyecto: 141.562 €. Coordinador (IP): Raoul Hervé.
5. Nombre del proyecto: Iberian network of laboratories of Biological Alert Acreditation of methods for detection of highly pathogenic agents/IB-BiOALERNET Entidad/es financiadora/s: DG-Home (Unión Europea). Fecha de inicio-fin: 2013 – 2015. Cuantía total: 629.382,67 €. Coordinador (IP): Carmen Cañavate
6. Nombre del proyecto: Desarrollo de nuevos métodos de diagnóstico e identificación de especies fúngicas causantes de neumonías oportunistas. Entidad/es financiadora/s: ISCIII. Fecha de inicio-fin: 2012 – 2015. Cuantía total: 67.429,67 €. Investigador principal: María José Buitrago.
7. Nombre del proyecto: European Research Infrastructure on Highly Pathogenic Agents 2-ERINHA2 (Horizon2020). Nombre del programa: FP7-Infraestructuras-2015. Programa marco. THEME (INFRA-2010-2.2.8: High Security BLS4 Laboratory. Entidad financiadora: Unión Europea. Fecha de inicio-fin: 01/01/2010 - 31/12/2013. Cuantía total: 4.859.782,5 €. Coordinador (IP): Raoul Hervé.
8. Nombre del proyecto: RED iberoamericana de diagnóstico molecular de las infecciones endémicas y oportunistas. Entidad/es financiadora/s: CYTED-AECI. Fecha de inicio-fin: 2008 – 2009. Cuantía total: 70.000 €. Investigador principal: Luz-Elena Cano
9. Nombre del proyecto: “Desarrollo de nuevos métodos de diagnóstico en alertas biosanitarias relacionadas con la Micología”. Entidad/es financiadora/s: Instituto de Salud Carlos III. Fecha de inicio-fin: 2007 – 2009. Cuantía total: 58.500 €. Investigador Principal: María José Buitrago
- Titulo: “Inmunidad entrenada en trasplante de órganos”.
Entidad financiadora. Ministerio de Ciencia, Innovación y Universidades
Referencia: Proyecto PID2019-110015RB-I00 financiado por MICIU/AEI/10.13039/501100011033
IP: Jordi Cano Ochando
Fechas de ejecución: 01/06/2020-31/05/2024
Presupuesto: 205.700 €
PROYECTOS VIGENTES
Título del proyecto: "Vesículas extracelulares y otras moléculas de parásitos para el tratamiento de la enfermedad inflamatoria intestinal: PARATREAT-IBD"
Referencia: Proyecto PID2022-137661OB-I00 (MPY 341/23) financiado por MCIN/AEI /10.13039/501100011033/ y por FEDER Una manera de hacer Europa
Fecha Inicio: 01/12/2023
Fecha Fin: 31/08/2026
Financiación: 162.500 Euros
Investigador principal: Javier Sotillo
Agencia Financiadora: Agencia Estatal de Investigación. MICINN.
Título del proyecto: "Desarrollo de nuevos métodos diagnósticos y de seguimiento de la infección por schistosoma haematobium"
Referencia: PI23CIII00034 / MPY 386/23
Fecha Inicio: 01/01/2024
Fecha Fin: 31/12/2026
Financiación: 131.500 Euros
Investigador principal: Javier Sotillo
Agencia Financiadora: Instituto de Salud Carlos III (ISCIII/AESI)
Título del proyecto: "Desarrollo de herramientas para el control de la teniosis / cisticercosis en zonas endémicas y vigilancia de las helmintosis humanas emergentes en España"
Referencia: PI22CIII/00010
Fecha Inicio: 01/01/2023
Fecha Fin: 31/12/2025
Financiación: 80.000 Euros
Investigador principal: María Jesús Perteguer
Agencia Financiadora: Instituto de Salud Carlos III (ISCIII/AESI)
PROYECTOS PASADOS
Título del proyecto: "PERITAS: Molecular epidemiological studies on pathways of transmission and longlasting capacity building to prevent cystic echinococcosis infection."
Coordinador: Adriano Casulli. IP of ISCIII: Maria J. Perteguer.
Entidad financiadora: EULAC Health JOINT CALL on Research and Innovation 016-2017
Periodo: 01/03/2019-31/12/2022.
Cuantía total: 1.083.580 €.
Título del proyecto: "Producción de antígenos y controles positivos recombinantes para el desarrollo y la estandarización de nuevos ensayos serológicos aplicados al diagnóstico y control de helmintosis olvidadas. "
Investigador principal: María Jesús Perteguer.
Entidad financiadora: ISCIII-AESI. Instituto de Salud Carlos III
Periodo: 02/11/2018 - 31/06/2022.
Cuantía total: 78.050 €.
Título del proyecto: "Diagnóstico serológico diferencial de helmintiasis asociadas a eosinofilia: desarrollo de ensayos multianalito (xMAP) con antígenos recombinantes de especies de interés clínico"
Investigador principal: María Jesús Perteguer.
Entidad financiadora: ISCIII-AESI. Instituto de Salud Carlos III
Periodo: 01/01/2015 - 31/12/2018 .
Cuantía total: 91.000 €.
Publications
Broadly cross-neutralizing antibodies in HIV-1 patients with undetectable viremia
Medina-Ramirez M, Sanchez-Merino V, Sanchez-Palomino S, Merino-Mansilla A, Ferreira CB, Perez I, Gonzalez N, Alvarez A, Alcocer-Gonzalez JM, Garcia F, Gatell JM, Alcami J, Yuste E; J Virol. 2011 Jun;85(12):5804-13.
PUBMED DOIIncrease in isolation of Burkholderia contaminans from Spanish patients with cystic fibrosis.
Medina-Pascual MJ, Valdezate S, Carrasco G, Villalón P, Garrido N, Saéz-Nieto JA. (2015) Increase in isolation of Burkholderia contaminans from Spanish patients with cystic fibrosis. Clin Microbiol Infect. ;21(2):150-6
PUBMED DOIPodocytes as new cellular targets of hemoglobin toxicity in massive intravascular hemolysis.
Rubio-Navarro A, Sanchez-Niño MD, Guerrero-Hue M, García-Caballero C, Gutiérrez E, Yuste C, Sevillano A, Praga M, Egea J, Román E, Cannata P, Ortega R, Cortegano I, de Andrés B, Gaspar ML, Cadenas S, Ortiz A, Egido J, Moreno JA. Podocytes as new cellular targets of hemoglobin toxicity in massive intravascular hemolysis. 2018. J.Pathol. 244(3):296-310.
PUBMED DOIAn increase in negative supercoiling in bacteria reveals topology-reacting gene clusters and a homeostatic response mediated by the DNA topoisomerase I gene
Ferrándiz MJ, Martín-Galiano AJ, Arnanz C, Camacho-Soguero I, Tirado-Vélez JM, de la Campa AG. 2016. Nucl Acids Res. 44:7292-7303 (2016).
PUBMED DOISpatially-restricted JAG1-Notch signaling in the human thymus provides permissive microenvironments for dendritic cell development.
Martín Gayo, E., González-García, S., García-León, M., Murcia-Ceballos, A., Alcain, J., García-Peydró, M., Allende, L., de Andrés, B., Gaspar, ML. and Toribio, ML. J.Exp.Med. (2017) 214:3361-3379
PUBMED DOIGenomic Background and Phylogeny of cfiA-Positive Bacteroides fragilis Strains Resistant to Meropenem-EDTA
Medina-Pascual MJ, Valdezate S, Carrasco G, Villalón P, Garrido N, Saéz-Nieto JA. (2015) Increase in isolation of Burkholderia contaminans from Spanish patients with cystic fibrosis. Clin Microbiol Infect. ;21(2):150-6.
PUBMED DOIEpidemiology of the Acinetobacter-derived cephalosporinase, carbapenem-hydrolysing oxacillinase and metallo-beta-lactamase genes, and of common insertion sequences, in epidemic clones of Acinetobacter baumannii from Spain
Villalón P, Valdezate S, Medina-Pascual MJ, Carrasco G, Vindel A, Saez-Nieto JA. Epidemiology of the Acinetobacter-derived cephalosporinase, carbapenem-hydrolysing oxacillinase and metallo-beta-lactamase genes, and of common insertion sequences, in epidemic clones of Acinetobacter baumannii from Spain. J Antimicrob Chemother. 2013;68(3):550-3.
PUBMED DOISimian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: replication, neutralization, and survey of HIV-1-positive plasma
Yuste E, Sanford HB, Carmody J, Bixby J, Little S, Zwick MB, Greenough T, Burton DR, Richman DD, Desrosiers RC, Johnson WE*. 2006. J Virol 80:3030-41.
PUBMED DOIThe formation of titan cells in Cryptococcus neoformans depends on the mouse strain and correlates with induction of Th2-type responses
García-Barbazán, I., Trevijano-Contador, N., Rueda, C., de Andrés, B., Pérez-Tavárez, R., Herrero-Fernández, I., Gaspar ML., and Zaragoza, O. Cellular Microbiology (2015) 18:111-124
PUBMED DOIPredicted HLA Class I and Class II Epitopes From Licensed Vaccines Are Largely Conserved in New SARS-CoV-2 Omicron Variant of Concern.
López, D. 2022. Predicted HLA Class I and Class II Epitopes From Licensed Vaccines Are Largely Conserved in New SARS-CoV-2 Omicron Variant of Concern. Front Immunol. 13:832889.
PUBMEDGarcia-Arriaza, J., M. Esteban, and D. López. 2021
Garcia-Arriaza, J., M. Esteban, and D. López. 2021. Modified Vaccinia Virus Ankara as a Viral Vector for Vaccine Candidates against Chikungunya Virus. Biomedicines. 9.
PUBMEDCross-Recognition of SARS-CoV-2 B-Cell Epitopes with Other Betacoronavirus Nucleoproteins
Tajuelo, A., M. López-Siles, V. Mas, P. Perez-Romero, J. M. Aguado, V. Briz, M. J. McConnell, A. J. Martín-Galiano, and D. López. 2022. Cross-Recognition of SARS-CoV-2 B-Cell Epitopes with Other Betacoronavirus Nucleoproteins. Int.J.Mol.Sci. 23.
PUBMEDAbundance, Betweenness Centrality, Hydrophobicity, and Isoelectric Points Are Relevant Factors in the Processing of Parental Proteins of the HLA Class II Ligandome.
Lorente, E., A. J. Martín-Galiano, D. M. Kadosh, A. Barriga, J. Garcia-Arriaza, C. Mir, M. Esteban, A. Admon, and D. López. 2022. Abundance, Betweenness Centrality, Hydrophobicity, and Isoelectric Points Are Relevant Factors in the Processing of Parental Proteins of the HLA Class II Ligandome. J.Proteome.Res. 21:164-171.
DOIPrediction of Conserved HLA Class I and Class II Epitopes from SARS-CoV-2 Licensed Vaccines Supports T-Cell Cross-Protection against SARS-CoV-1.
López, D. 2022. Prediction of Conserved HLA Class I and Class II Epitopes from SARS-CoV-2 Licensed Vaccines Supports T-Cell Cross-Protection against SARS-CoV-1. Biomedicines. 10.
PUBMED DOIPredicted Epitope Abundance Supports Vaccine-Induced Cytotoxic Protection Against SARS-CoV-2 Variants of Concern.
Martín-Galiano, A. J., F. Diez-Fuertes, M. J. McConnell, and D. López. 2021. Predicted Epitope Abundance Supports Vaccine-Induced Cytotoxic Protection Against SARS-CoV-2 Variants of Concern. Front Immunol. 12:732693.
PUBMED DOIde la Sota, P. G., E. Lorente, L. Notario, C. Mir, O. Zaragoza, and D. López. 2021. Mitoxantrone Shows In Vitro, but Not In Vivo Antiviral Activity against Human Respiratory Syncytial Virus. Biomedicines. 9.
de la Sota, P. G., E. Lorente, L. Notario, C. Mir, O. Zaragoza, and D. López. 2021. Mitoxantrone Shows In Vitro, but Not In Vivo Antiviral Activity against Human Respiratory Syncytial Virus. Biomedicines. 9.
PUBMED DOILorente, E., M. Marcilla, P. G. de la Sota, A. Quijada-Freire, C. Mir, and D. López. 2021. Acid Stripping after Infection Improves the Detection of Viral HLA Class I Natural Ligands Identified by Mass Spectrometry. Int.J.Mol.Sci. 22.
Lorente, E., M. Marcilla, P. G. de la Sota, A. Quijada-Freire, C. Mir, and D. López. 2021. Acid Stripping after Infection Improves the Detection of Viral HLA Class I Natural Ligands Identified by Mass Spectrometry. Int.J.Mol.Sci. 22.
PUBMED DOIRedondo-Anton, J., M. G. Fontela, L. Notario, R. Torres-Ruiz, S. Rodriguez-Perales, E. Lorente, and P. Lauzurica. 2020. Functional Characterization of a Dual Enhancer/Promoter Regulatory Element Leading Human CD69 Expression. Front Genet. 11:552949.
Redondo-Anton, J., M. G. Fontela, L. Notario, R. Torres-Ruiz, S. Rodriguez-Perales, E. Lorente, and P. Lauzurica. 2020. Functional Characterization of a Dual Enhancer/Promoter Regulatory Element Leading Human CD69 Expression. Front Genet. 11:552949.
PUBMED DOILorente, E., E. Barnea, C. Mir, A. Admon, and D. López. 2020. The HLA-DP peptide repertoire from human respiratory syncytial virus is focused on major structural proteins with the exception of the viral polymerase. J Proteomics. 221:103759.
Lorente, E., E. Barnea, C. Mir, A. Admon, and D. López. 2020. The HLA-DP peptide repertoire from human respiratory syncytial virus is focused on major structural proteins with the exception of the viral polymerase. J Proteomics. 221:103759.
PUBMED DOILorente, E., M. G. Fontela, E. Barnea, A. J. Martín-Galiano, C. Mir, B. Galocha, A. Admon, P. Lauzurica, and D. López. 2020. Modulation of Natural HLA-B*27:05 Ligandome by Ankylosing Spondylitis-associated Endoplasmic Reticulum Aminopeptidase 2 (ERAP2). Mol.Cell Proteomics. 19:994-1004.
Lorente, E., M. G. Fontela, E. Barnea, A. J. Martín-Galiano, C. Mir, B. Galocha, A. Admon, P. Lauzurica, and D. López. 2020. Modulation of Natural HLA-B*27:05 Ligandome by Ankylosing Spondylitis-associated Endoplasmic Reticulum Aminopeptidase 2 (ERAP2). Mol.Cell Proteomics. 19:994-1004.
PUBMED DOI-
Ana Alastruey Izquierdo
Research Scientist
ORCID code: 0000-0001-8651-4405
Doctor in microbiology from the Complutense University of Madrid and Master in Bioinformatics and computational biology from the same university. He completed his doctoral thesis at the ISCIII under the supervision of Dr. Juan Luis Rodríguez Tudela in molecular identification of human pathogenic fungi. He carried out research stays in Holland (Fungal Biodiversity Center, CBS-Knaw, Utrecht) and Austria (Austrian Institute of Technology). In 2010-2011 he joined Dr. David Perlin's group as a postdoctoral fellow at the Public Health Research Institute of Rutgers University in the United States working on antifungal resistance. In 2012 and 2013 he carried out research stays at the European Bioinformatics Institute (EMBL-EBI). Since 2014 he has been a Senior Scientist at the ISCIII.
-
María Cabrerizo Sanz
Tenure Scientist and Group Leader
ORCID code: 0000-0001-7054-5696
Doctor in Chemistry, specializing in Biochemistry and Molecular Biology, Universidad Autónoma de Madrid (2000). Except for a postdoctoral period of 2 years at the Hospital de La Princesa, in which her research was related to onco-hematological diseases, the rest of her scientific career has focused on the study of infectious diseases caused by viruses and their surveillance. She joined the Instituto de Salud Carlos III in 2003, first in the Laboratory of Arbovirus and Imported Viral Diseases, then in the Laboratory of Viral Hepatitis and finally, in the Laboratory of Enterovirus (which is accredited as a National Polio Laboratory -LNP- for the WHO since 1998). She obtained the position of Tenure Scientist in 2016, at the same time she assumed the responsibility of the laboratory, currently of Enteric Viruses: Poliovirus/Enterovirus, Parechovirus and Gastroenteritis-producing Viruses, of the CNM. She has 4 scientific sexennials and 4 quinquennials recognized.
She has been and is PI of 4 consecutive research projects and 3 service contracts, from 2012 to the present, participating, in addition, in other 20 projects. As head of the LNP, she is part of the Working Group of the National Plan for the Eradication of Poliomyelitis and of the WHO European Polio Laboratory Network. She is also a member of the European Non-Polio Enterovirus Network (ENPEN), and of the national cooperation networks CIBERESP and RITIP (IdiPAZ). Since 2023 she is a Council Member from Spain of the European Society.
In total she has published 98 articles in WoS indexed journals (23 Q1 and 22 D1), being first author, senior author or correspondence author in 43 of them (H=27). She has supervised 1 PhD Thesis (2017) and 12 TFM. She is currently supervising another doctoral thesis (IMIENS-UNED). She participates as a teacher in three university masters (UCM, UAH and UV), being coordinator of the subject H2 of the Master of Virology at UCM.
-
Javier García Pérez
Investigador Doctor
ORCID code: 0000-0001-7551-7803
Graduated in Biochemistry (1999) and Molecular Biology (2000) from the Autonomous University of Madrid (UAM), he obtained a predoctoral fellowship “ISCIII” in the AIDS Immunopathology laboratory, where he developed new techniques based on recombinant viruses. His doctoral thesis focused on the application of this technological development to the study of the replicative capacity of HIV-1 and its resistance to antiretroviral drugs, obtaining the degree of Doctor of Science from the UAM in 2007.
Thanks to a short postdoc in 2008 and several stays between 2009 and 2015 at the Viral Pathogenesis Unit of the Institut Pasteur in Paris he extended his training in the study of HIV-1 envelope and tropism. Between 2015 and 2019 he rejoins the AIDS Immunopathology Unit at ISCIII, focusing his work on the study of the functional capacity of founder viruses, as well as variants of the virus with interest in Public Health due to its recent expansion in our country. He is currently leading a project on the study of a mutation in transportin 3 observed in patients with a very rare muscular dystrophy (LGMDD2) that confers protection against HIV-1 infection.
During the last 5 years he combines this activity in HIV-1 with the participation and leadership of different clinical trials and studies investigating the immunity generated in people vaccinated against SARS-CoV-2 infection.
Since 2024 he is a “Investigador Doctor fuera de Convenio” at the Spanish National Centre of Microbiology and he currently coordinates together with Dr. Francisco Díez Fuertes the AIDS Immunopathology Unit.
-
María Luisa Gaspar Alonso-Vega
Research Professor
ORCID code: 0000-0001-9858-3862
Dr. María Luis Gaspar Alons-Vega graduated in 1980 and obtained her PhD in 1985 in Medicine and Surgery from the Autonomous University of Madrid. She completed the specialty of Immunology (1981-1985), and her doctoral thesis under the direction of Dr. Carmen Gutierrez, in the Immunology laboratory of the Puerta de Hierro Clinic directed by Dr. Miguel Kreisler. She completed a predoctoral stay in the Cytogenetics Laboratory of the National Institute of Autoimmune, Diabetes, Digestive and Kidney Diseases (NIDDK, NIH), under the supervision of Dr. JH Tjio and Dr. E. Raveché. She joined the Immunology Service of the National Center for Health Microbiology, Virology and Immunology (CNMVIS, AISNA and later ISCIII) as a Physician-Specialist in 1986, in the Immunology Laboratory directed by Dr. Alfredo Toraño. She completed a postdoctoral stay (1989-1991) at the Immunogenetics Unit of the Pasteur Institute (Paris) directed by Dr. T. Meo. From 1991 to 2006 she was Head of the Immunology Section successively at the CNMVIS, at the National Center for Fundamental Biology (CNBF-ISCIII) and at the National Center for Microbiology (CNM-ISCIII). From 2006 to 2016 she has been a Senior Researcher and Senior Scientist of OPIs, in the Immunobiology laboratory of the CNM-ISCIII. From 2016 to 2018 she was a Scientific Researcher at OPIs and since 2018, she is a Research Professor at OPIs at the CNM.
-
Horacio Gil Gil
Research Scientist
ORCID code: 0000-0002-7114-6686
Degree in Veterinary Medicine in 1995 and PhD in Veterinary Medicine in 2002 from the University of Zaragoza. He did his PhD thesis at NEIKER Tecknalia (Derio, Vizcaya) and the National Center for Microbiology of Instituto de Salud Carlos III (CNM-ISCIII, Majadahonda, Madrid) on the biological cycle of Lyme disease in the Basque Country. After that, he developed his postdoctoral training in different aspects of the pathogenesis of tularemia at the Center for Infectious Diseases, Stony Brook University, New York (USA) for 3 years. In December 2005, he joined the Reference and Research Laboratory in Special Pathogens of the CNM-ISCIII where he developed diagnostic, reference and research activities, in Bartonella, Leptospira and pathogens of interest in bioterrorism. Between 2014-2016 he participated in the European Program for the Training of Microbiologists in Public Health (EUPHEM), organized by the European Centre for Disease Prevention and Control. During this program, he participated in an international mission for the investigation of a cholera outbreak in Ghana, proposed by the Bernhard Nocht Institute for Tropical Diseases in Hamburg (Germany). In December 2016, he worked as a laboratory consultant for the World Health Organization at their office in Phnom Penh (Cambodia). Subsequently, he worked one year with Médecins Sans Frontières as director and quality manager of the TB laboratory in Nukus (Uzbekistan).
In 2019, he joined the HIV Variability and Biology Unit at CNM-ISCIII, where he developed different reference and research activities, including his contribution to the molecular epidemiological surveillance of HIV-1 in Spain and the study of HIV-1 antiretroviral resistance. Since September 2022 he has been leading the Human Papillomavirus Unit at the CNM-ISCIII. -
Adela González de la Campa
Scientific Investigator
ORCID code: 0000-0002-3598-2548
Dr. Adela González de la Campa obtained her degree in Biology in 1981 and her PhD in 1985 from the Complutense University of Madrid. She did her doctoral thesis in the laboratory of Dr. Miguel Vicente at the Centro de Investigaciones Biológicas of CSIC. Subsequently she worked for 2 years at Brookhaven National Laboratory, Upton, New York, USA in the laboratory of Sandford Lacks. After this postdoctoral stage in the USA, she worked for 3 years as a Reincorporation Fellow at the Centro de Investigaciones Biológicas of CSIC in the laboratory of Dr. Manuel Espinosa. He is a CSIC Senior Scientist since 1990 and Research Scientist since 2007. He participated as group leader of the CIBER of Respiratory Diseases (CIBERES) from 2007 to 2015. Since 1990, she has been the principal investigator of the Bacterial Genetics Unit at the National Centre for Microbiology.
-
Maribel Jiménez Alonso
Tenured Scientist
ORCID code: 0000-0002-5615-3087
Doctor in Pharmacy from the Complutense University of Madrid (1994) and Extraordinary Doctorate Award. She started her research activity at ISCIII in 1990 in the field of leishmaniasis. Currently, she is the head of the LEM where she develops her scientific work in the field of entomological surveillance of phlebotomine sandflies in the CM and other studies in the field of molecular biology, mainly applied to the model of Leishmania infantum and its vector Phlebotomus perniciosus. Member of the team of experts of the ISCIII that participates in the elaboration of Rapid Risk Assessments and in the working groups in charge of the elaboration of National Plans of Prevention, Surveillance and Control of Vector-borne Diseases of the CCAES, Ministry of Health. She is currently “Operational Focal Point” for vector-borne diseases at national level for the One Health-Vectornet network (EFSA and ECDC) and coordinator of the VectorNet-Spain network since July 2024. In addition, she is a member of the expert committee of the Network of Surveillance and Control of Vectors with public health interest in the Community of Madrid. In addition, she is part of a research group from CIBER (CIBERINFEC; CB21/13/00110).
-
Vicente Mas Lloret
Scientific Researcher
-
-
Eloisa Yuste Herranz
Staff Scientist
ORCID code: 0000-0002-9484-9974
She holds a Bachelor's and a Ph.D. in Biological Sciences from the Complutense University of Madrid. She completed her first postdoctoral stay (1998–2001) at the “Severo Ochoa” Molecular Biology Center (Madrid). In 2001, she undertook a second postdoctoral stay at Harvard Medical School (USA), where she was promoted to Associate Researcher in 2005.
In 2008, she joined the August Pi i Sunyer Biomedical Research Institute (Barcelona) as a Ramón y Cajal Researcher, later being promoted to I3 Researcher in 2011 at the same institution. In 2016, she joined the National Center for Microbiology at the Carlos III Health Institute (Madrid) as a Distinguished Researcher. In 2018, she was promoted to Tenured Scientist at the same institution.
Her research has focused on the study of humoral immunity against HIV-1 and the development of preventive HIV-1 vaccine prototypes. She is currently co-leading, alongside Dr. Víctor Sánchez Merino, the newly established Humoral Immunity and HIV Vaccines Unit.
-
Óscar Zaragoza Hernández
Research Professor
ORCID code: 0000-0002-1581-0845
Dr. Oscar Zaragoza graduated in Biology from the Complutense University of Madrid in 1995 and obtained his PhD from the Autonomous University of Madrid. He completed his doctoral thesis (2000) at the CSIC under the direction of Dr. Juana María Gancedo on the topic of glucose catabolite repression in Saccharomyces cerevisiae. During this period, he was also tutored by Dr. Carlos Gancedo in collaborative projects, that allowed him to start working with the pathogenic yeast Candida albicans.
After a brief postdoctoral stay in the same laboratory, in 2001, he joined the laboratory of Dr. Arturo Casadevall (Albert Einstein College of Medicine, New York), where he specialized in research into virulence mechanisms of pathogenic fungi, mainly Cryptococcus neoformans. In 2006 he joined the National Center for Microbiology of the ISCIII thanks to a “Ramón y Cajal” contract and he became staff scientist in 2009. Currently, he occupies the rank of Research Professor of the OPIs.
During his career, he has published more than 140 articles, 4 book chapters and a popular book ("Microscopic fungi: Friends or Enemies?"). He has obtained public and private projects, and participates as CoIP of a CIBERINFEC group. He has supervised seven doctoral theses, and numerous master's thesis projects.
-
Laura Alguacil Cuéllar
PhD student (pFIS)
ORCID code: 0000-0002-7362-0214
Graduated in Biology from the Rey Juan Carlos University, she completed the Master's Degree in Microbiology and Parasitology: Research and Development from the Complutense University of Madrid (UCM) and is an expert in Research Methodology and Evidence-Based Clinical Practice from the Miguel de Cervantes European University. For two years he was a research assistant in the Microbiology department of the Faculty of Pharmacy at the UCM thanks to a CM Young Employment Scholarship. In 2023 he joined ISCIII with a pFIS predoctoral contract under the direction of Dr. Ana Alastruey Izquierdo.
-
Jorge Amich Elías
Tenure Scientist
ORCID code: 0000-0002-8987-5115
Doctor en Microbiología y Genética Molecular, realizó su tesis doctoral (2010) en la Universidad de Salamanca bajo la dirección del Dr. José Antonio Calera Abad. Realizó estancias postdoctorales en la Universidad de Würzburg (Alemania) bajo la supervisión del Prof. Sven Krappmann (2011-2012) y en el Hospital Clínico de Würzbug bajo la supervisión del Prof. Andreas Beilhack (2013-2015). Entre 2016 y 2021 fue Investigador Principal en el Manchester Fungal Infection Group (MFIG, Universidad de Manchester, Reino Unido) financiado con un MRC Career Development Award. En 2022 me he incorporado al Centro Nacional de Microbiología del ISCIII gracias a un contrato de Atracción de Talento de la Comunidad de Madrid. En 2024, pasó a ser Científico Titular de los OPIs en el CNM.
-
Belén de Andrés Muguruza
Research Scientist
ORCID code: 0000-0002-7391-2823
Graduated in Biology in 1987 and PhD in 1992 from the Autonomous University of Madrid. He completed his doctoral thesis in the laboratory of Dr. Carlos Lahoz in the Immunology department of the Jiménez Díaz Foundation with a pre-doctoral stay at the Institute Curie in Paris, in the laboratory of Dr. Wolf H. Fridman. Subsequently, he completed a two-year postdoctoral stay in the Department of Pathology of the College of Medicine at the University of Iowa, USA, in the laboratory of Dr. Richard G. Lynch. After a year as an Adjunct in the Immunology department of the Jiménez Diaz Foundation, she worked for 2 years with a reinstatement contract from the Ministry of Science in the Immunobiology department of the CNM/ISCIII in the laboratory of Dr. Mª Luisa Gaspar and later with a Ramón y Cajal contract. In 2006 she obtained a position as Staff Senior Scientist.
-
Francisco Díez Fuertes
Investigador Doctor Indefinido
ORCID code: 0000-0003-2413-9229
Degree in Biology from the University of León, PhD specialized in molecular virology from the Complutense University of Madrid in 2010 and master's degree in bioinformatics and computational biology from the same university in 2012. He has done research stays at University of Illinois at Urbana Champaign (USA) in 2010, Nebraska Center for Virology (USA) in 2011, Institut Pasteur (France) in 2013 and J. Craig Venter Institute (USA) in 2015-2016.
He joined the AIDS Immunopathology Unit in 2013 with a contract from the “Sara Borrell” postdoctoral program. After a period at the August Pi i Sunyer Biomedical Research Institute in Barcelona he rejoins the AIDS Immunopathology Unit in 2020 as a PhD researcher.
His lines of research have focused on the genomic and transcriptomic characterization of extreme phenotypes in HIV-1 infection, including long-term non-progressors and elite controllers. He collaborates with other laboratories of the center in the analysis of outbreaks caused by viruses with interest in Public Health, as well as in evolutionary studies on genomic epidemiology. Since 2020 he has led different clinical studies on COVID-19. Currently, he combines omics sciences with different bioinformatics tools to answer different scientific questions in the field of virology, especially in HIV-1 and SARS-CoV-2 research. He currently coordinates together with Dr. Javier García Pérez the AIDS Immunopathology Unit.
-
Mª Dolores Fernández García
Tenure Scientist
ORCID code: 0000-0003-0336-6596
Degree in Pharmacy (2005) and PhD from the University VII Paris Diderot in Microbiology (2010). She completed her doctoral thesis at the Pasteur Institute in Paris characterizing the molecular and cellular basis of flavivirus entry into cells. Specialist in Public Health Microbiology (European Program EUPHEM coordinated by ECDC). She has worked 3 years for the French Ministry of Foreign Affairs as a researcher at the Pasteur Institute in Dakar (Senegal) carrying out microbiological surveillance activities and research on polioviruses and non-polio enteroviruses in West Africa. She has obtained two Miguel Servet contracts: one to work at IMIBIC in Cordoba (2019) and an intramural one to work at CNM (2020). Both were awarded for the study of neurotropic viruses applying massive sequencing for their diagnosis. In 2021 he joined the CNM-ISCIII as a Tenure Research Scientist at the Enterovirus and Viral Gastroenteritis Unit of the CNM-ISCIII. Since then, she combines her scientific activity with the assistance to the National Health System in the microbiological research of outbreaks and in the Genomic Surveillance of Enteroviruses and Gastroenteritis-producing Viruses.
She is a researcher in the Epidemiology and Public Health Area of the Centro de Investigación Biomédica en Red (CIBERESP-ISCIII). In addition, she is an evaluator and panelist for the HORIZON health program projects of the European Commission, the French National Agency ANRS-Emerging Infectious Diseases, R&D&I in HEALTH of the Strategic Action in Health (ISCIII) and the Andalusian Public Foundation Progreso y Salud. She has worked as scientific advisor to the Spanish Ministry of Health on Rotavirus and Polio. Since 2020 she has been teaching virology in different Spanish universities.
She has worked for WHO in the investigation of numerous outbreaks caused by viruses (Ebola, Zika, Yellow Fever, Dengue, etc.) in African and Asian countries strengthening laboratory capacities through technology transfer of diagnostic methods, training of laboratory personnel in these countries and scientific advisory tasks to the Ministries of Health. She has been the Health Coordinator of the START Project (Spanish Technical Aid Response Team) of the AECID, framed in the “Emergency Medical Teams” initiative of the WHO, participating in the establishment for Spain of a field hospital classified by the WHO as EMT Level 2 for interventions in humanitarian emergencies.
-
María José Ferrándiz Avellano
Research Scientist
ORCID code: 0000-0003-1428-9506
Dr. María José Ferrández obtained her degree in Biology in 1990 and her PhD in 1997 from the Complutense University of Madrid. She completed her doctoral thesis at the Centro de Investigaciones Biológicas of CSIC in the laboratory of Dr. Miguel Vicente. She completed her postdoctoral training at the Centro Nacional de Microbiología of Instituto de Salud Carlos III (1998-2001 and 2003-2006) and at the Institute of Infection and Immunity (University of Nottingham) from 2001- 2003. From 2007 to 2015, she participated as a researcher of the CIBER of Respiratory Diseases (CIBERES). Since 2006, she is a Full Scientist at the National Microbiology Center of the ISCIII.
-
-
Jose Antonio Infantes Lorenzo
Project-Associated Researcher
-
Inés Martín Martín
Tenured Scientist
ORCID code: 0000-0002-0956-7324
Within Medical Entomology, my work focuses on the study of phlebotomine sand flies and culicidae as vectors of leishmaniasis and arbovirosis, respectively. In 2014 I obtained my PhD degree “cum laude” with European mention from the Complutense University of Madrid. My PhD Thesis (developed at the Instituto de Salud Carlos III), focused on the study of phlebotomine sandfly saliva. Subsequently, during my postdoctoral period, I worked on insect gene editing, molecular, biochemical and functional characterization of insect saliva proteins and their role in the infection and transmission of pathogens. Most of my scientific career has been developed at the Laboratory of Malaria and Vector Research, National Institutes of Health (NIH), USA. Since 2021 I am a Senior Scientist at the Laboratory of Medical Entomology (ISCIII).
List of staff
Additional Information
The Respiratory Viruses and Influenza Unit is the oldest WHO Influenza Center in our country (1968), designated as the National Influenza Center by the Ministry of Health in 1971, and is the national coordinator of the CCAA laboratories in the National Influenza Surveillance Network of the Influenza Surveillance System in Spain.
Its general objective is virological surveillance, detection and control of influenza in Spain. Since 1992, together with the Pediatric Service of the Severo Ochoa Hospital, a line of research has been developed based on the etiological study of viral respiratory infections in hospitalized children.
Since 2015, the La Paz Children's University Hospital and the Immunology Laboratory of the IIS-Fundación Jiménez Díaz have also participated, expanding the study to newborns and neonatal units.
To comprehensively study respiratory viruses and the response of the immune system in viral respiratory infections that affect newborns and pediatric patients.
Deepen the knowledge of the biological properties of the viruses involved in the disease: dependency/facilitation, balance between viruses and their adaptation in multiple infections, relationship with severity, existence of virome imbalance.
The Respiratory Viruses and Influenza Unit is the oldest WHO Influenza Center in our country (1968), designated as the National Influenza Center by the Ministry of Health in 1971, and is the national coordinator of the CCAA laboratories in the National Influenza Surveillance Network of the Influenza Surveillance System in Spain.
Its general objective is virological surveillance, detection and control of influenza in Spain. Since 1992, together with the Pediatric Service of the Severo Ochoa Hospital, a line of research has been developed based on the etiological study of viral respiratory infections in hospitalized children.
Since 2015, the La Paz Children's University Hospital and the Immunology Laboratory of the IIS-Fundación Jiménez Díaz have also participated, expanding the study to newborns and neonatal units.
To comprehensively study respiratory viruses and the response of the immune system in viral respiratory infections that affect newborns and pediatric patients.
Deepen the knowledge of the biological properties of the viruses involved in the disease: dependency/facilitation, balance between viruses and their adaptation in multiple infections, relationship with severity, existence of virome imbalance.